Seeking Alpha

Reed Research

 
View as an RSS Feed
PRO Articles
PRO articles cover stocks that fly under most investors' radar screens.
  • Evaluating Sucampo's Upside Potential
       • Fri, Jun. 27 SCMP 3 Comments

    Summary

    • Sucampo has solid fundamentals, science and partnerships.
    • Revenue is projected to grow by ~20% in the next 2 years.
    • Sucampo has upside potential.
  • Exact Sciences Is A Near-Term Short Due To Risks And Assumptions About Its Future Business
       • Fri, Apr. 11 EXAS 18 Comments

    Summary

    • Exact Sciences is currently overvalued with the assumption of PMA approval.
    • The assumed $300 premium pricing by CMS and future sales figures are far from certain.
    • With both near term risks and assumptions, EXAS is a near-term short.
  • The Long-Term Risks About Ocera Therapeutics
       • Mon, Mar. 17 OCRX 10 Comments

    Summary

    • Hepatic Encephalopathy market is competitive.
    • Ocera has yet to show a convincing advantage over other alternatives.
    • Ocera's OCR002 molecule faces a fundamental risk.
  • Analysis Of The Near-Term Value Drivers Of Spectrum Pharmaceuticals
       • Fri, Mar. 7 SPPI 6 Comments

    Summary

    • Analysis of the 6 key value drivers of SPPI.
    • Revenue growth of Fusilev, Marqibo and Fotolyn are key.
    • Over 50% CAGR for revenue possible if SPPI can fully leverage these value drivers.
  • Analysis Of Intercept Pharmaceuticals And OCA's Future Potential
       • Nov. 19, 2013 ICPT 13 Comments